The primary objective of the trial is to establish the effectiveness of IAT (versus medical management) in patients with moderate-large infarcts (NCCT ASPECTS 2-5) at baseline, with adaptive enrichment to better define the upper limit of infarct volume for treatment eligibility. Furthermore, the investigators aim to determine whether certain subgroups of patients with large baseline infarcts will have a greater treatment benefit. Finally, the investigators will assess the agreement of ASPECTS scores between site investigators, the core imaging lab, and automated software.
Prospective, randomized, open-label, blinded endpoint study. Patients presenting with symptoms of AIS who have evidence of a moderate-large infarct volume (Non-contrast CT Alberta Stroke Program Early CT score [NCCT ASPECTS] 2-5 in the anterior circulation will be assigned to either best medical management alone (including IV rtPA) or intra-arterial treatment (IAT) with mechanical thrombectomy added to best medical management. Each treated patient will be followed and assessed for 3 months after randomization.
SIMR (Sacramento/Valley Area): Please contact SIMR@sutterhealth.org about study The Tesla Trial
CPMC (San Francisco: Davies & Van Ness): Please contact firstname.lastname@example.org about study The Tesla Trial
MPMC (Mills Peninsula-Burlingame): Please contact email@example.com about study The Tesla Trial
Using Electronic Health Records to Identify Gaps in Migraine Headache Care: A Step Towards Improving Patient Outcomes
Investigator: Sylvia Sudat, PhD